Clene Nanomedicine, researching the use of gold atoms to slow ALS progression, nets $42.5M Series D
A biopharma that uses gold to develop treatments for neurodegenerative diseases just got a little bit richer.
Clene Nanomedicine pulled in $42.5 million in a Series D financing round Wednesday, money which will go toward advancing its lead program through a Phase III platform trial in ALS and support Phase II trials in MS, Parkinson’s disease and ALS. CEO Rob Etherington said that by the end of 2021, Clene will know whether or not the candidate, called CNM-Au8, will prove effective.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.